Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Quinapril · 4 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Quinapril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg |
| 2 | ACTIVE_COMPARATOR | Accuretic™ Tablets 20 mg/25 mg |
| Name | Type | Description |
|---|---|---|
| Quinapril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg | DRUG | 20/25mg, single dose fed |
| Accuretic™ Tablets 20 mg/25 mg | DRUG | 20/25mg, single dose fed |
| Quinapril Hydrochloride Tablets 40 mg | DRUG | 40mg, single dose fasting |
| Accupril® Tablets 40 mg | DRUG | 40mg, single dose fasting |
Inclusion Criteria: 1. Age: 18 years and older. 2. Sex: Male and/or non-pregnant, non-lactating female. 1. Women of childbearing potential must have negative serum beta-human chorionic gonadotropin (HCG) pregnancy tests performed within 14 days prior to the start of the study and on the evening...
Quinapril is a small molecule angiotensin converting enzyme (ACE) inhibitor developed by Viatris Inc. (ticker VTRS). It is available as quinapril hydrochloride tablets and in combination with hydrochlorothiazide. The clinical trials listed for quinapril are Phase 1 studies conducted in healthy volunteers in the United States.
Quinapril targets angiotensin converting enzyme (ACE) and acts as an ACE inhibitor. By inhibiting ACE, quinapril reduces the formation of angiotensin II, which leads to vasodilation and reduced aldosterone secretion. This mechanism underlies its use in cardiovascular conditions, though the specific indications studied in its clinical program are not disclosed.
Quinapril is developed by Viatris Inc., which trades under the ticker VTRS. Viatris is the sponsor of the clinical trials evaluating quinapril hydrochloride tablets and quinapril HCl and hydrochlorothiazide tablets.
Quinapril is in Phase 1 clinical development. All four of its listed trials are Phase 1 studies, and all four are completed. There are currently no active trials. The trials enrolled a total of 188 participants and were conducted in the United States.
Quinapril has been studied in four completed Phase 1 trials: NCT00649649, a food study of quinapril hydrochloride 40 mg tablets versus Accupril 40 mg tablets; NCT00649441, a fasting study of quinapril HCl and hydrochlorothiazide 20 mg/25 mg versus Accuretic 20 mg/25 mg; NCT00649103, a fasting study of quinapril hydrochloride 40 mg versus Accupril 40 mg; and NCT00648011, a food study of quinapril HCl and hydrochlorothiazide 20 mg/25 mg versus Accuretic 20 mg/25 mg.